Rocket Pharmaceuticals
RCKT
82 hedge funds and large institutions have $109M invested in Rocket Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 10 closing their positions.
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
35% more call options, than puts
Call options by funds: $6.46M | Put options by funds: $4.77M
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
16.53% more ownership
Funds ownership: 0% → 16.53% (+17%)
5% more funds holding
Funds holding: 78 → 82 (+4)
47% less capital invested
Capital invested by funds: $207M → $109M (-$98M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$10M |
| 2 |
Millennium Management
New York
|
+$1.21M |
| 3 |
Goldman Sachs
New York
|
+$1.15M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$807K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$722K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.34M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$3.31M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.02M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.89M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.71M |
RCKT Hedge Fund Activity: Q4 2016 in Review
82 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2016, worth a combined $109M — down 47% from $207M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RCKT positions and 10 closed out — a net gain of 5 holders — while 30 added to existing stakes and 24 trimmed.
The largest buyer was Great Point Partners, adding an estimated $10M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $8.34M sold.
- 82 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2016, up from 78 in Q3 2016.
- Funds reported $109M of Rocket Pharmaceuticals stock for Q4 2016, down 47% quarter-over-quarter.
- 15 funds opened new Rocket Pharmaceuticals positions in Q4 2016 and 10 closed out, a net change of +5 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2016 was Great Point Partners, an estimated $10M added.
- The largest Rocket Pharmaceuticals seller in Q4 2016 was Point72 Asset Management, an estimated $8.34M sold.
Based on aggregated 13F filings for Q4 2016.